Verastem reported $202.9M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Alaunos Therapeutics USD 666K 304K Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Curis USD 16.61M 9.7M Mar/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Laboratory Of America USD 3.97B 151.3M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
TG Therapeutics USD 1.17B 25.76M Sep/2026
Verastem USD 202.9M 20.51M Mar/2026